Back to Dashboard










Amgen Inc. (AMGN)
Real-time intraday values
Market Overview
From:
To:
AMGN Intraday
No data available
SymbolAMGN
IPO DateJun 17, 1983
CEOMr. Robert A. Bradway
Full Time Employees31.5k
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUnited States
ExchangeNasdaqGS
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | +0.86% | +3.49 US$ |
| 5 Days | +6.19% | +23.88 US$ |
| 1 Month | -7.00% | -30.81 US$ |
| 6 Months | +17.42% | +60.76 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of AMGN...
Key Statistics
Market Cap
221.41B
P/E Ratio
25.41
Div Yield
2.48%
52W High
$447.03
52W Low
$269.77
Analyst Consensus
ConsensusHold
Bullish1235.3%
Neutral1750.0%
Bearish514.7%
52W Analyst Price Targets
Min Target
$225.00
$225.00
Max Target
$457.00
$457.00
Current$409.53
Avg Target$389.22
Analyst Recommendations
Target Price:$389.22($225.00 - $457.00)
Community Thoughts
Share your analysis and sentiment on AMGN
Join the community to share your analysis
Latest News for AMGN

Keystone To Launch India Business With Bengaluru As First Hub, Plans To Hire Talent & Increase Workforce Over Next Two Years
PR Newswire•Sep 25, 2026, 02:00 PM

Bet on These 5 Dividend Growth Stocks Amid Rising Treasury Yields
Zacks•Sep 25, 2026, 12:28 PM

Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Zacks•Sep 25, 2026, 12:00 PM

The Peptide Boom That Isn’t About Your Muscles
The Wall Street Journal•Sep 25, 2026, 09:30 AM

How Investors Are Reacting To Veeva Systems (VEEV) Expanding Agentic AI And Winning New Pharma Clients
Simply Wall St.•Sep 25, 2026, 06:10 AM

Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks
StockStory•Sep 24, 2026, 09:12 PM

Can Eli Lilly Stock Catch Up To Rivals It Outgrows?
Trefis•Sep 24, 2026, 07:03 PM

How a Roth IRA Can Keep Thousands More of Your DJIA Dividend Income Compounding
24/7 Wall St.•Sep 24, 2026, 03:58 PM

UPLIZNA Market Poised for Growth Through 2034 as Expanding Indications and Rising Demand Drive Sales Opportunities
GlobeNewswire•Sep 24, 2026, 08:34 AM

Amgen (AMGN) Is Up 7.9% After Positive Phase 3 Dazodalibep Data in Systemic Sjögren’s Disease
Simply Wall St.•Sep 24, 2026, 01:14 AM